Patients with various Blood Malignancies who are candidates for Autologous Hematopoietic Stem Cell Transplantation.. Stem cells transplant status
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged between18 -70 years old who are candidates for autologous bone marrow stem cell transplantation Informed consent to enter the study No pregnanct and lactation Minimum interval of 4 weeks between the last cycle of chemotherapy and entering the study Serum creatinine = 2.2 mg/dL Liver function test (AST, ALT) below three times the upper limit normal
Exclusion criteria
Exclusion criteria: History of allergy to G-CSF Receiving Filgrastim or Peg-filgrastim during 2 and 3 weeks before entering the study, respectively
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD34 count. Timepoint: daily. Method of measurement: Flow cytometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of side effects of headache, bone pain, muscle pain, flu-like symptoms, and fatigue. Timepoint: daily. Method of measurement: Clinical observation during daily visits.;Engraftment time. Timepoint: daily. Method of measurement: Measuring Blood cells count.;Incidence of febrile neutropenia. Timepoint: daily. Method of measurement: Measuring blood cell counts and body temperature.;Incidence of thrombocytopenia. Timepoint: daily. Method of measurement: Measuring blood cell counts.;Incidence of documented infection. Timepoint: daily. Method of measurement: Clinical sign and symptoms and laboratory data.;The need to plerixafor injection. Timepoint: During mobilization. Method of measurement: Registering and reporting the number of patients who need to be prescribed Plerixafor in each study group. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shahid Beheshti University of Medical Sciences